Affordable Access

Botulinum toxin type B for treatment of spasmodic dysphonia: a case report.

Authors
  • Sataloff, Robert Thayer1
  • Heman-Ackah, Yolanda D
  • Simpson, Lance L
  • Park, Jong-Beak
  • Zwislewski, Amy
  • Sokolow, Caren
  • Mandel, Steven
  • 1 Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Phillyent.com
Type
Published Article
Journal
Journal of Voice
Publisher
Elsevier
Publication Date
Sep 01, 2002
Volume
16
Issue
3
Pages
422–424
Identifiers
PMID: 12395995
Source
Medline
License
Unknown

Abstract

Although treatment with botulinum toxin type A (BTXA) has become the standard of care for most patients with laryngeal dystonia, its use is limited by the development of resistance to the toxin in some patients. Botulinum toxin type B (BTXB) has been found to be safe and effective in the treatment of cervical dystonia, but it has not been used previously to treat spasmodic dysphonia. Our experience with BTXB in a patient who developed resistance to BTXA suggests that BTXB may be safe and effective for the treatment of laryngeal dystonia, as well.

Report this publication

Statistics

Seen <100 times